AZN

AstraZeneca PLC Ordinary Shares (AZN) Stock Analysis

Research AstraZeneca PLC Ordinary Shares (AZN) with company financials, earnings context, valuation indicators, risk analysis and related market news.

Research record updated: . Individual measures may refer to different reporting periods.

Ticker
AZN
Company
AstraZeneca PLC Ordinary Shares
Sector
Healthcare
Industry
Drug Manufacturers - General
Market cap
$245.98B
Financial data source
FMP financial statements + FMP cash flow statements + FMP balance sheet + income statements
Annual revenue (reporting year not supplied)
$58.74B
Annual net income (reporting year not supplied)
$10.26B
Annual free cash flow (reporting year not supplied)
$8.67B
Trailing revenue
$61.37B
Trailing net income
$10.45B
Total assets
$114.07B
Total liabilities
$65.36B

AstraZeneca PLC Ordinary Shares (AZN) Stock Analysis research

AstraZeneca PLC is a global biopharmaceutical company developing and selling prescription medicines across oncology, cardiovascular, renal and metabolic disease, respiratory care, immunology, and rare disorders. Its portfolio includes Tagrisso, Imfinzi, Farxiga, Symbicort, Fasenra, and Ultomiris, supported by a broad late-stage pipeline. Recent Seeking Alpha and comparable market coverage has generally highlighted durable oncology growth, regulatory milestones, trial updates, and the importance of replacing future revenue exposed to patent expiry. Key potential catalysts include datopotamab deruxtecan, camizestrant, next-generation antibody-drug conjugates, and obesity-related research. Antibody-drug conjugates act like targeted delivery systems, carrying potent treatment directly toward cancer cells, while bispecific antibodies can engage two biological targets at once; AI-assisted discovery and radioconjugates could further improve precision and speed development. The principal debate is whether pipeline execution and acquisitions can offset legal, regulatory, competitive, and patent-related pressure. Within Healthcare, AstraZeneca combines large-cap scale, above-average innovation, and strong growth prospects, although its valuation is richer than many established pharmaceutical peers and recent momentum has been weak relative to the broader market. Sector score: 8/10; based on competitive strength, diversification, pipeline quality, and cash generation, the shares represent a high-quality healthcare holding, but not an obvious bargain. The figures suggest a profitable, cash-generating business with substantial assets and manageable but meaningful leverage, while the premium valuation leaves less room for disappointing trials, slower launches, pricing pressure, or patent losses. Recent price weakness and only modest risk-adjusted performance imply cautious sentiment, yet continued operating cash flow and a deep pipeline support a constructive longer-term outlook. Neutral

Review the available company profile, financial history, valuation context and investor signals for AstraZeneca PLC Ordinary Shares. Compare the reported operating results with the valuation and risk measures below.

The figures are cached research data and can change after new filings, earnings reports or market updates. Verify material facts with primary company disclosures before making an investment decision.